HeartSciences Inc. (NASDAQ:HSCS) Short Interest Down 28.5% in February

by · The Cerbat Gem

HeartSciences Inc. (NASDAQ:HSCS – Get Free Report) was the recipient of a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 29,772 shares, a drop of 28.5% from the January 29th total of 41,615 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily volume of 20,331 shares, the short-interest ratio is currently 1.5 days. Based on an average daily volume of 20,331 shares, the short-interest ratio is currently 1.5 days. Approximately 1.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on HSCS shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Monday, December 29th. Ascendiant Capital Markets upped their price objective on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research note on Monday, December 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.20.

Check Out Our Latest Stock Report on HeartSciences

Institutional Trading of HeartSciences

Several hedge funds have recently modified their holdings of the company. DRW Securities LLC grew its holdings in shares of HeartSciences by 13.7% in the fourth quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock valued at $294,000 after purchasing an additional 11,455 shares in the last quarter. Geode Capital Management LLC raised its stake in HeartSciences by 110.7% during the fourth quarter. Geode Capital Management LLC now owns 26,928 shares of the company’s stock valued at $83,000 after purchasing an additional 14,150 shares in the last quarter. Finally, TFB Advisors LLC bought a new position in HeartSciences during the third quarter valued at $105,000. 17.24% of the stock is owned by hedge funds and other institutional investors.

HeartSciences Stock Performance

HSCS traded down $0.13 during trading on Monday, hitting $2.66. 7,873 shares of the company traded hands, compared to its average volume of 14,819. The stock’s 50-day simple moving average is $3.07 and its two-hundred day simple moving average is $3.12. HeartSciences has a 1 year low of $2.01 and a 1 year high of $6.47.

HeartSciences (NASDAQ:HSCS – Get Free Report) last released its quarterly earnings data on Monday, December 15th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.05. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, sell-side analysts forecast that HeartSciences will post -10.01 earnings per share for the current fiscal year.

HeartSciences Company Profile

(Get Free Report)

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.

Featured Articles